Aviceda Therapeutics Revenue

Biotechnology Research • Cambridge, Massachusetts, United States • 21-50 Employees

Aviceda Therapeutics revenue & valuation

Annual revenue	$3,111,111
Revenue per employee	$76,000
Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues	$10,000,000
Total funding	$223,100,000

Key Contacts at Aviceda Therapeutics

Emmett Cunningham

Member Of The Board Of Directors

Kinkini Roy

Associate Director, Drug Product Development

Michael Tolentino

Co-Founder, Head Scientific Consultant To The Ceo

Jeffrey Nau

Chief Executive Officer

Anitha Krishnan

Executive Director-Research

Jack Markey

Executive Director, Technical Accounting

Amitkumar Lad

Senior Director: Technical Development

Nrupa Ρatel

Associate Director Drug Product Ms&T

Ravinder Earla

Associate Director

Jeffrey Silva

Director Of Finance

Company overview

Headquarters	One Broadway, 14th Floor, Cambridge, Massachusetts 02142, US
Phone number	+16172254343
Website	avicedarx.com
NAICS	541714
SIC	873
Founded	2018
Employees	21-50
Socials

Aviceda Therapeutics Email Formats

Aviceda Therapeutics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@avicedarx.com), used 59.3% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@avicedarx.com	59.3%
{first name}{last name}	johndoe@avicedarx.com	40.7%

About Aviceda Therapeutics

The Future of Glyco-therapeutics Aviceda Therapeutics is a disruptive clinical-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly using a propriety HALOS platform Technology. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic degenerative, fibrotic, and immuno-inflammatory diseases. A combination of cutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation. Aviceda has combined the power of our glycobiology and glycochemistry platform with our proprietary nanoparticle technology (HALOS) to engineer transformative disease modifying medicines. Using our cell-based high-throughput screening (HTS) platform, we can rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. Optimized ligands are tethered to our modular biodegradable nanoparticles using high precision conjugation chemistry to form biologically stable linkages. Our GCT nanoparticles are designed for optimal therapeutic durability and maximum therapeutic efficacy while utilizing the most effective route of administration. Aviceda’s platform is highly adaptable, enabling the development of a broad spectrum of therapeutics for immuno-inflammatory indications with large unmet medical needs.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Director

Entry

C-Suite

Employees by Department

Aviceda Therapeutics has 16 employees across 9 departments.

Departments

Number of employees

Funding Data

Explore Aviceda Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount	Link to Article
2023-06-19	1	$15,600,000
2025-02-07	6	$207,500,000

Funding Insights

$223,100,000

Total funding amount

$207,500,000

Most recent funding amount

Number of funding rounds

Aviceda Therapeutics Tech Stack

Discover the technologies and tools that power Aviceda Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Fathom

Analytics

HSTS

Security

Netlify

CDN

Frequently asked questions

Aviceda Therapeutics is located in Cambridge, Massachusetts, US.

You can reach Aviceda Therapeutics at +16172254343.

Aviceda Therapeutics generates an estimated annual revenue of $3,111,111. This revenue figure reflects the company's market position and business performance in its industry.

Aviceda Therapeutics has an estimated valuation of $10,000,000. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.

Aviceda Therapeutics was founded in 2018, making it 8 years old. The company has established itself as a significant player in its industry over this time.

Aviceda Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

Aviceda Therapeutics has raised a total of $223,100,000 across 2 funding rounds. This investment has helped the company grow and expand its operations.